**Key figures**

- 60 staff
- 20 on-going studies
- Over 65,000 followed-up patients

**Leadership and expertise**

- **European projects**
  - ARITMO - Arrhythmogenic potential of drugs
    - FP7 Work Package partner
  - Eu-ADR - Early detection of adverse drug events
    - FP7 Work Package leader
  - SOS - Safety of NSAIDs
    - FP7 Work Package leader
  - SALT - Study of Acute Liver Transplant
    - Project leader - project at the request of EMEA

- **Training programmes**
  - Eu2P - European Training programme in Pharmacovigilance and Pharmacoepidemiology
    - Master's of Science, PhD, Continuing Education
    - FP7 project leader - funding
  - PEP Master & DIU - National Master's of Science & Continuing Education postgraduate diploma in Pharmacoepidemiology and Pharmacovigilance
    - Training programme leader - Université Bordeaux 2

- **Expert group and society membership**
  - ISoP - International Society of Pharmacovigilance
  - ISPE - International Society of Pharmacepidemiology
  - EACPT - European Association of Clinical Pharmacology and Therapeutics
  - ENCePP - European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

**Contact**

**Contacts**

- Nicholas Moore
- Bernard Bégaud - Mathieu Molimard
- Annie Fourrier-Réglat - Patrick Blin

**Département de Pharmacologie**

Université de Bordeaux
CHU de Bordeaux
INSERM U657
INSERM-CHU CIC 0005
Bâtiment du Tondu - Case 41
146, rue Léo Saignat
33076 Bordeaux Cedex
FRANCE

[www.pharmacoepi.eu](http://www.pharmacoepi.eu)

Tel.: +33 5 57 57 15 60 / 46 75
Fax: +33 5 57 57 47 40
pharmacoepi@u-bordeaux2.fr
We are highly skilled in the full process of real life medicines evaluation.

We have in house competencies in Medicine, Pharmacy, Pharmacology, Epidemiology and Biostatistics, and work with a network of independent experts in Paris, Montreal, Rotterdam, Barcelona, ...

Our staff has continuously expanded and covers the full range of activities involved in pharmacoepidemiology studies adhoc and in claims databases.

We cover major medical fields: cardiology, hepato-gastroenterology, neurology, oncology, pneumology, rhumatology, spa therapy...

The results of our studies participate in the implementation of guidelines to optimise the benefits and to minimise the risks of medicines to better public health.

**Core competencies**

**Leadership**
- Scientific Experts

**Investigation**
- Coordinator
- Project Managers
- Study Managers
- Clinical Research Assistants
- Administrative Agents

**Support teams**
- IT & Database
- Statistics
- Data-Management
- Critical Event Validation
- Fund-Raiser
- Lawyer

**Valorisation**
- Medical Writer
- Multimedia Support

---

**Pharmacoepidemiology studies**

**EOLE**
Impact on mortality of cardiovascular drugs used for secondary prevention of myocardial infarction
- 5,492 AMI patients included
- National cohort study at the request of the health authorities, supported by the French Society of Cardiology and the National College of French Cardiologists

**SALT**
Study of acute liver failure leading to registration for transplantation in patients exposed to non-steroidal anti-inflammatory drugs
- 801 patients expected
- European, multicentre, retrospective case-population study at the request of European Medicines Agency (EMEA)
- Transplant centres in 7 EU countries

**EULEV**
Prescription modalities and effectiveness of levetiracetam in the treatment of epilepsy in a real-life setting
- 794 adults & 156 children included
- National children and adults cohorts study at the request of the health authorities, supported by the French neurologist association

**COLCHIC**
Evaluation of chemotherapy practices in patients with colorectal cancer
- 204 patients included
- Cohort study evaluating professional practices in a single University Hospital

**ETNA**
Evaluation of the survival at 12-months of patients with metastatic colorectal cancer treated by bevacizumab
- 413 patients included
- Multiregion multicentre cohort study supported by the national clinical research programme

**SANTORIN**
Evaluation of the survival at 24 months of patients with metastatic renal cancer treated by anti-angiogenic drugs
- 350 patients expected
- Multiregion multicentre cohort study

**VESUVE**
Evaluation of the use and effectiveness of bortezomib, a proteasome inhibitor, in the treatment of multiple myeloma
- 794 patients included
- National cohort study at the request of the health authorities

**ABSINTHE**
Impact of therapeutic strategy in acute sinusitis in real-life medical practice by GPs and otorhinolaryngologists
- 5,693 patients included
- National cohort study at the request of the health authorities

**THEATRE**
Impact of the initial strategy for chronic obstructive pulmonary disease exacerbation by GPs and pulmonologists
- 1,011 patients included
- National cohort study at the request of the health authorities

**CADEUS**
Description of the real-life use of coxibs and traditional non-steroidal anti-inflammatory drugs
- 46,554 patients included
- National cohort study at the request of the health authorities
- Use of national reimbursement database and field data

**PRISME**
Evaluation of dietetic, physical and psychological care in metabolic syndrome and the quality of life of patients undertaking spa therapy
- 139 patients included
- Single centre cohort study

**PSOLEMEE**
Evaluation of treatment cost in chronic plaque psoriasis
- 770 patients expected
- National medico-economic study

More information on pharmacoepidemiology studies at [www.pharmacoepi.eu](http://www.pharmacoepi.eu)

We are part of the INSERM U657 research network